Novo Nordisk, Europe’s most valuable drugmaker, will accelerate its US expansion at the expense of the EU unless Brussels changes a plan to reform regulation of the industry, the company’s chief executive has said.
Lars Fruergaard Jørgensen said much of the Danish company’s research was now done in Boston and “the journey of expanding in the US would be further accelerated” if the EU implemented its new pharmaceutical rules that would cut drugmakers’ years of market exclusivity.
Jørgensen, president of EFPIA, the industry association, spoke on Friday as he launched a study outlining the dramatic impact the plan would have — creating what he called a “negative ecosystem”.
Read more about Novo Nordisk here.
This article was originally published by Www.ft.com. Read the original article here.